WALTHAM, Mass., Oct. 28, 2015 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases, including hormone responsive metastatic breast cancer, announced today that it will release its third quarter 2015 financial results on Thursday, November 5, 2015.
In connection with the earnings release, Radius Health will host a conference call and live audio webcast at 7:30 a.m. EST on Thursday, November 5, 2015 to discuss the results, and give an update on the Company's progress.
Conference Call Information:
Date: Thursday, November 5, 2015
Time: 7:30 a.m. EST
Domestic Dial-in Number: 1-888-329-8889
International Dial-in Number: 1-719-457-2631
Live webcast: http://public.viavid.com/index.php?id=116965
For those unable to participate in the conference call or live webcast, a replay will be available beginning November 5, 2015 at 10:30 a.m. EST until December 5, 2015 at 11:59 p.m. EST. To access the replay, dial 1-877-870-5176. The replay passcode is 2546529.
A live audio webcast of the call will also be available on the Investors section of the Company's website, www.radiuspharm.com. A webcast replay will be available for 30 days on the Radius website, www.radiuspharm.com. The full text of the announcement and financial results will also be available on the Company's website.
About Radius Health
Radius is a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers. Radius' lead development candidate is the investigational drug abaloparatide for subcutaneous injection, currently in Phase 3 development for potential use in the reduction of fracture risk in postmenopausal women with severe osteoporosis. The Radius clinical portfolio also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug RAD1901 for potential use in hormone driven, or hormone resistant, metastatic breast cancer, and vasomotor symptoms. www.radiuspharm.com
Investor Relations Barbara Ryan Partner Clermont Partners 203-274-2825 email@example.com